NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Chairman Buys $46,800.00 in Stock

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Chairman Jonathan C. Javitt bought 40,000 shares of the stock in a transaction that occurred on Tuesday, December 17th. The shares were purchased at an average cost of $1.17 per share, with a total value of $46,800.00. Following the purchase, the chairman now directly owns 84,634 shares of the company’s stock, valued at $99,021.78. The trade was a 89.62 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

NRx Pharmaceuticals Trading Down 1.3 %

NASDAQ NRXP opened at $1.50 on Friday. The company’s 50 day moving average is $1.28 and its two-hundred day moving average is $1.86. NRx Pharmaceuticals, Inc. has a 12 month low of $1.10 and a 12 month high of $7.33. The stock has a market cap of $18.14 million, a price-to-earnings ratio of -0.70 and a beta of 1.25.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. EF Hutton Acquisition Co. I upgraded NRx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 21st. HC Wainwright reiterated a “buy” rating and issued a $19.00 price objective on shares of NRx Pharmaceuticals in a report on Monday, November 25th. Finally, Ascendiant Capital Markets boosted their price objective on NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Monday, December 2nd.

Institutional Trading of NRx Pharmaceuticals

An institutional investor recently bought a new position in NRx Pharmaceuticals stock. Townsquare Capital LLC purchased a new stake in shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 15,041 shares of the company’s stock, valued at approximately $25,000. Townsquare Capital LLC owned 0.14% of NRx Pharmaceuticals as of its most recent filing with the SEC. 4.27% of the stock is owned by institutional investors and hedge funds.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.